Pharmacokinetics in children
Rapid distribution. Only for short-term treatment in IC. The slow elimination becomes relevant as the length of treatment increases.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Status epilepticus |
- Intravenous
-
1 month
up to
18 years
- Initial dose:
5
mg/kg/dose,
bolus.
- Maintenance dose:
5
mg/kg/hour,
continuous infusion. Max: 10 mg/kg/hour.
- Loading: Preferably with EEG monitoring. Repeat the loading dose every 20 minutes until a burst suppression of 30 seconds is obtained or the epileptiform activity has disappeared.
- Maintenance: raise the dosage as necessary in steps of 1-2 mg/kg/hour to a maximum of 10 mg/kg/hour.
- Reduce: Once the status is under control (both clinically and on the EEG), cut back the thiopental gradually over 12-24 hours (e.g. 25% of the initial rate every 6 hours)
- Relapses: repeat the loading dose and revert to the old infusion rate for 24-72 hours.
|
| Anaesthesia: induction |
- Intravenous
-
2 years
up to
18 years
-
1 month
up to
2 years
-
Term neonate
|
| Thiopental coma: refractory intracranial hypertension |
|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Depression of respiration and cardiac output. Skin reactions because of histamine release. Tissue necrosis on extravasation.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications in children
Absolute contraindication: Porphyria.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Watch out for blood pressure drops, reduced resistance, fever and (on prolonged used) impaired liver function.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ANESTHETICS, GENERAL
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Halogenated hydrocarbons |
|
|
|
N01AB07
|
|
|
|
N01AB06
|
|
|
|
N01AB08
|
| Opioid anesthetics |
|
|
|
N01AH02
|
|
|
|
N01AH01
|
|
|
|
N01AH06
|
|
|
|
N01AH03
|
| Other general anesthetics |
|
|
|
N01AX01
|
|
|
|
N01AX14
|
|
|
|
N01AX07
|
|
|
|
N01AX10
|
References
-
Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
-
Werkgroep Richtlijnen Epilepsie, Epilepsie. Richtlijnen voor diagnostiek en behandeling, Nederlandse Vereniging voor Neurologie en de Nederlandse Liga tegen Epilepsie, Herziene, tweede versie, januari 2006
-
Waardenburg van DA, et al, Richtlijn status epilepticus kinderen ouder dan één maand., Nederlandse Vereniging voor Kindergeneeskunde, Augustus 2005
-
Hospira Benelex BVBA, SPC Pentothal (RVG 11772), 05/17, Geraadpleegd 19 jan 2022, https://www.geneesmiddeleninformatiebank.nl/smpc/h11772_smpc.pdf
-
Panpharma GMBH, SmPC Thiopental Pulver zur Herstellung einer Injektionslösung (43552.00.00) , Jan 2020
-
Panpharma GMBH, SmPC Thiopental Pulver zur Herstellung einer Injektionslösung (43552.00.00), Jan 2020
Therapeutic Drug Monitoring
Overdose